검색어 : 통합검색[Wilhelm Horst]
총 483건 중 483건 출력
, 49/49 페이지
-
481
- Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG)
- Paschka, Peter; Schlenk, Richard F.; Ibañ ez, Mariam; Kagias, Alexandra; Bullinger, Lars; Gaidzik, Verena I.; Spä th, Daniela; Horst, Heinz A.; Held, Gerhard; Bentz, Martin; Kremers, Stephan; Greil, Richard; Wattad, Mohammed; Brugger, Wolfram; Runde, Volker; Raghavachar, Aruna; Derigs, Hans-Guenter; Kirchen, Heinrich; Dö hner, Hartmut; Dö hner, Konstanze; Universitä tsklinikum Ulm, Ulm, Germany,; Universitä tsklinikum Ulm, Ulm, Germany,; Universitä tsklinikum Ulm, Ulm, Germany,; Universitä tsklinikum Ulm, Ulm, Germany,; Universitä tsklinikum Ulm, Ulm, Germany,; Universitä tsklinikum Ulm, Ulm, Germany,; Universitä tsklinikum Ulm, Ulm, Germany,; Universitä tsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany,; Universitä tsklinikum des Saarlandes, Homburg, Germany,; Stä dtisches Klinikum Karlsruhe, Karlsruhe, Germany,; Caritas-Krankenhaus Lebach, Lebach, Germany,; Salzburger Universitä tsklinikum, Salzburg, Austria,; Kliniken Essen Sued, Essen, Germany,; Klinikum der Stadt Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany,; Wilhelm-Anton-Hospital GmbH, Goch, Germany,; HELIOS Klinikum Wuppertal, Wuppertal, Germany,; Klinikum Frankfurt Hö chst GmbH, Frankfurt am Main, Germany,; Krankenhaus der Barmherzigen Brü der Trier, Trier, Ger; (Blood, v.116, 2010, pp.101-101)
-
482
- Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
- Schä fer, Niklas; Proescholdt, Martin; Steinbach, Joachim P; Weyerbrock, Astrid; Hau, Peter; Grauer, Oliver; Goldbrunner, Roland; Friedrich, Franziska; Rohde, Veit; Ringel, Florian; Schlegel, Uwe; Sabel, Michael; Ronellenfitsch, Michael W; Uhl, Martin; Grau, Stefan; Hä nel, Mathias; Schnell, Oliver; Krex, Dietmar; Vajkoczy, Peter; Tabatabai, Ghazaleh; Mack, Frederic; Schaub, Christina; Tzaridis, Theophilos; Nießen, Michael; Kebir, Sied; Leutgeb, Barbara; Urbach, Horst; Belka, Claus; Stummer, Walter; Glas, Martin; Herrlinger, Ulrich; Division of Clinical Neuro-oncology, Department of Neurology, University of Bonn, Bonn, Germany; Department of Neurosurgery, University of Regensburg, Regensburg, Germany; Dr Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany; Department of Neurosurgery, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany; Department of Neurology and Wilhelm Sander Neuro-Oncology Unit, University Hospital Regensburg, Regensburg, Germany; Department of Neurosurgery, University of Mü nster, Mü nster, Germany; Department of Neurosurgery, University of Cologne, Cologne, Germany; Department of Radiation Oncology, University of Leipzig, Leipzig, Germany; Department of Neurosurgery, University of Goettingen, Goettingen, Germany; Department of Neurosurgery, Klinikum rechts der Isar Technical University of Munich, Munich, Germany; Department of Neurology, Ruhr-Universitä t Bochum, Bochum, Germany; Department of Neurosurgery, U; (Neuro-oncology, v.20, 2018, pp.975-985)
-
483
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
- Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Sabel, Michael; Hau, Peter; Kortmann, Rolf-Dieter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Schnell, Oliver; Bä hr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Kowalski, Thomas; Ringel, Florian; Schmidt-Graf, Friederike; Suchorska, Bogdana; Brehmer, Stefanie; Weyerbrock, Astrid; Renovanz, Miriam; Bullinger, Lars; Galldiks, Norbert; Vajkoczy, Peter; Misch, Martin; Vatter, Hartmut; Stuplich, Moritz; Schä fer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Stummer, Walter; Tonn, Jö rg-Christian; Simon, Matthias; Keil, Vera C; Nelles, Michael; Urbach, Horst; Coenen, Martin; Wick, Wolfgang; Weller, Michael; Fimmers, Rolf; Schmid, Matthias; Hattingen, Elke; Pietsch, Torsten; Coch, Christoph; Glas, Martin; Division of Clinical Neurooncology, Department of Neurology and Centre of Integrated Oncology, University Hospital Bonn; Division of Clinical Neurooncology, Department of Neurology and Centre of Integrated Oncology, University Hospital Bonn; Division of Clinical Neurooncology, Department of Neurology and Centre of Integrated Oncology, University Hospital Bonn; Dr Senckenberg Institute of Neurooncology, University of Frankfurt; Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr-Universitä t Bochum; Department of Neurosurgery, University of Dü sseldorf; Department of Neurology and Wilhelm Sander Neurooncology Unit, University Hospital Regensburg; Department of Radiation Oncology, University of Leipzig; Department of Neurosurgery,; (The Lancet, v.393, 2019, pp.678-688)
QUICK MENU
